RxSight, Inc. (NASDAQ:RXST) Stock Holdings Lifted by Osterweis Capital Management Inc.

Osterweis Capital Management Inc. boosted its stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 48.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 288,072 shares of the company's stock after buying an additional 93,827 shares during the quarter. Osterweis Capital Management Inc. owned approximately 0.71% of RxSight worth $9,904,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Private Trust Co. NA acquired a new position in shares of RxSight during the fourth quarter valued at about $34,000. Arcadia Investment Management Corp MI acquired a new position in shares of RxSight in the fourth quarter worth about $46,000. Harbor Investment Advisory LLC acquired a new position in RxSight in the 4th quarter worth about $52,000. Global Retirement Partners LLC acquired a new stake in RxSight in the 4th quarter valued at $69,000. Finally, KBC Group NV grew its position in shares of RxSight by 71.0% in the fourth quarter. KBC Group NV now owns 2,107 shares of the company's stock valued at $72,000 after purchasing an additional 875 shares during the period. 78.78% of the stock is currently owned by institutional investors.

Insider Activity at RxSight

In other news, Director Tamara Fountain sold 7,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the transaction, the director now directly owns 24,793 shares of the company's stock, valued at approximately $637,428.03. This represents a 22.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Shweta Maniar sold 3,519 shares of the firm's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total value of $108,631.53. Following the completion of the sale, the director now directly owns 7,383 shares in the company, valued at approximately $227,913.21. This trade represents a 32.28 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.36% of the company's stock.

Wall Street Analyst Weigh In

RXST has been the topic of several recent research reports. JPMorgan Chase & Co. reaffirmed an "underweight" rating and set a $17.00 target price (down previously from $40.00) on shares of RxSight in a research note on Friday, April 4th. Stifel Nicolaus dropped their price objective on shares of RxSight from $33.00 to $28.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. Wells Fargo & Company decreased their target price on shares of RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 3rd. UBS Group cut RxSight from a "buy" rating to a "neutral" rating and cut their price target for the company from $45.00 to $16.00 in a report on Wednesday, April 9th. Finally, Piper Sandler started coverage on RxSight in a research note on Tuesday, April 15th. They set a "neutral" rating and a $18.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, RxSight has a consensus rating of "Hold" and a consensus target price of $37.60.

RxSight Trading Up 1.9 %

RXST traded up $0.27 during trading on Tuesday, hitting $14.47. 222,048 shares of the company's stock were exchanged, compared to its average volume of 617,070. The firm has a market cap of $585.70 million, a P/E ratio of -17.45 and a beta of 1.26. RxSight, Inc. has a 1 year low of $13.50 and a 1 year high of $66.54. The stock has a 50 day moving average price of $23.42 and a 200 day moving average price of $34.71.

RxSight (NASDAQ:RXST - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). The company had revenue of $40.21 million during the quarter, compared to analyst estimates of $40.23 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. Analysts forecast that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.